Leen Kawas, Athira CEO (Athira)
Can a small biotech successfully tackle an Everest climb like Alzheimer’s? Athira has $85M and some influential backers ready to give it a shot
There haven’t been a lot of big venture rounds for biotech companies looking to run a Phase II study in Alzheimer’s.
The field has been …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
